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Abstract

Available evidence points toward an epigenetic process in Alzheimer’s disease. This
thesis describes the research that was done to investigate changes in DNA methylation
using an in vitro model of the disease. Although the results indicated no global changes in
methylation levels after treating differentiated IMR-32 cells with beta amyloid, there
were several regions of the genome that changed their methylation status. Gene ontology
studies revealed that these regions are associated with neuronal differentiation and cell
fate genes, thus providing a possible model for the contribution of beta amyloid to the
development of Alzheimer’s disease. This study provides incentive to further study the
epigenetic processes in Alzheimer’s disease and explore avenues to reverse such
epigenetic changes.
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Effects of Beta Amyloid on the DNA Methylation Status of an in Vitro Model
of Alzheimer’s Disease
Introduction
Statement of the Problem
The classic hallmarks of Alzheimer’s disease (AD) are the presence of
neurofibrillary tangles (NFTs) and beta amyloid plaques. The terminal abnormal cellular
conditions of this neurodegenerative disease are well researched; however, the genetic
factors that may play a role in the development of the disease remain less clear.
Moreover, the epigenetic factors that cells use to modulate the DNA sequence are even
less clear. Although several lines of evidence suggest that epigenetic modifications, like
DNA methylation, might play a role in Alzheimer’s disease, it remains to be determined
if an epigenetic signature can be a telltale sign of AD development.
The identification of epigenetic marks associated with AD development would
provide excellent diagnostic markers for mapping AD progression and propose an
epigenetic model to how show AD initially begins. In addition, a non-mutational,
reversible process like DNA methylation would be vulnerable to the development of
epigenetic therapeutics aimed at preventing or even undoing age-related changes to the
genome. This thesis represents a novel line of research that may lead to significant
progress in our understanding of AD progression and the biology of aging.
Background
Epigenetics. The cytosine of the 5’-CpG-3’ dinucleotide serves as the target for
DNA methylation. Approximately 40% of human promoters contain CpG rich domains
that typically contain low levels of DNA methylation (1, 2). The presence or absence of
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the methyl mark across the DNA landscape can regulate the binding of various
transcription factors to the promoter regions. For instance, the transcription factor Ets-1
binds to its recognition sequence upstream of the Foxp3 gene promoter only when that
sequence is devoid of DNA methylation. Because this sequence is normally methylated
in most tissues, Ets-1 binding (and thus Foxp3 promoter activation) is typically inhibited
(3). On the other hand, transcriptional repressors like MeCP2 require CpG methylation
near promoter regions in order to bind DNA and ultimately repress transcription (1).
Since CpG methylation can either prevent the binding of factors that promote
transcription or enable the binding of transcriptional repressors, gene silencing is the
major biological outcome of DNA methylation (4) although exceptions are sure to exist
(5).
Unlike mutational changes in the genome, epigenetic marks (such as the posttranslational modification of histones and the methylation of cytosines) can dynamically
alter the local chromatin environment which results in dynamic changes in gene
expression and genomic stability (see (6) for a review). Interestingly, changes in genomic
methylation patterns are strongly associated with various disease states such as cancer
and syndromes involving mental retardation (7). These disease-associated epigenetic
changes produce an overall hypomethylated genome, although some portions of the
genome have restricted regions of CpG hypermethylation (8, 9). Understanding where
these specific epigenetic changes have occurred will not only highlight the genomic
regions most likely responsible for the overall disease pathology, it will also provide
useful targets for future therapies.
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Alzheimer’s Disease. Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the presence of neurofibrillary tangles (NFTs) and amyloid plaques. The
production of these structures results, in part, by the accumulation of
hyperphosphorylated tau (10-13) and Aβ peptide (14, 15), respectively. While normal tau
proteins add stability to microtubule structures, hyperphosphorylated tau leads to
microtubule disassembly and a breakdown of the neuronal cytoskeleton (11). Likewise,
Aβ deposits can produce neuronal, endothelial and glial cell death through several
apoptotic pathways (16, 17). Even though several of the aberrant cellular conditions of
AD are well known, the initial genetic factors which contribute to the development of AD
are unclear.
Gene expression studies have been conducted to determine some of the
transcriptional changes that result from artificial Aβ peptide treatments. These studies
were quite limited in their scope either because they were conducted in undifferentiated
neuroblastoma cells (18) or because only a portion of the transcriptome (1,176 genes in
mouse) was examined (19). Although more expression data are needed to accurately
describe the status of AD cells, the underlying cause of these differences in promoter
activity is even more important. This includes the epigenetic contributions, such as DNA
methylation, which serve to modulate base-line DNA sequences in the neuronal cells.
Epigenetics and AD. Several lines of evidence suggest that epigenetic
modifications, like DNA methylation, play a role in AD. First, late onset Alzheimer’s
disease, which represents over 90% of AD cases, appears sporadic in nature with no
known genetic cause (20). Consistent with this, the inheritance pattern of AD in twins
suggests a non-Mendelian mode of acquiring the disease (21-23) indicating that DNA
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sequence alone does not explain AD development. Second, evidence of a parent-oforigin effect has been described for AD identifying several genomic regions that are
transmitted through the maternal line to affected individuals (24). The requirement of an
environmental contribution (in this case being the maternal germ line) is consistent with
an epigenetic mechanism (25). It is interesting to note that one of the most common
mechanisms of parent-of-origin effects is “genomic imprinting” mediated by DNA
methylation (26). Third, studies in mice and humans suggest a global change in DNA
methylation when comparing AD subjects to their control counterparts. In humans,
monozygotic twins discordant for AD displayed differential DNA methylation levels in
the anterior temporal neocortex, a region severely affected in AD (27). The regions of the
brain not affected by AD displayed identical DNA methylation levels demonstrating the
specificity of this result. The specific reduction of DNA methylation in the AD twin may
provide a rationale for the link between folate deficiency and AD, since one of the normal
functions of folate is to donate methyl groups for DNA methylation reactions (28).
Finally, the expression levels of several AD-associated genes (APP, β-APP cleaving
enzyme, and neprylisin) are regulated based on the DNA methylation status of their
respective promoters (29, 30). It is important to note that although AD is associated with
a global hypomethylation of the genome, the neprylisin (31) promoter actually becomes
hypermethylated in murine cerebral endothelial cells treated with Aβ (30). This evidence
demonstrates that a gene can be affected by an epigenetic change that increases or
decreases its normal methylated state. NEP (neprylisin) expression is significantly
reduced in AD brains most likely due to methylation-dependent silencing (30, 32). Taken
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together, these data strongly suggest that DNA methylation plays a key role in the
development of AD.
Although the information presented above provides a strong link between DNA
methylation and AD, the specific pattern of genomic methylation has yet to be
determined in an AD model system for all human promoters. Furthermore, it remains to
be determined if an epigenetic signature can be indicative of AD development and
possibly useful in the diagnosis and treatment of the disease. Revealing the specific
regions of epigenetic change will not only shed light on the molecular process of AD
development, but it will also indicate the regions most vulnerable to the development of
future AD therapeutics.
Determining Methylated DNA Sequences
Several methods have been described that detect the presence of methylated
DNA. The methods used for determining methylated CpGs will be discussed here.
Bisulfite sequencing (33) utilizes the chemical differences between methylated and
unmethylated cytosine. Sodium bisulfite reacts with normal cytosine (unmethylated) to
form a sulfonated cytosine that can easily be deaminated to form sulfonated uracil.
Following the removal of the sulfonate group by alkaline conditions, the template can be
used in a standard polymerase chain reaction (PCR) reaction using Taq polymerase.
Since Taq recognizes uracil as thymine, the resulting PCR product will have a thymine at
locations corresponding to unmethylated cytosines. Methylated cytosines, on the other
hand, are protected from the chemical transitions to uracil so no changes in PCR product
are detected (see (34) for review). Although reliable, this method is not easily adapted to
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meet the requirements of a genomic-sized examination since sequencing at this scale is
quite expensive.
A spin off of the bisulfite sequencing method utilizes PCR primers to discriminate
between methylated and unmethylated templates (35). Primers are designed to overlap
with the CpG region of interest. After the template is treated with sodium bisulfite to
convert unprotected cytosines to uracil, methylation-specific primers are used to anneal to
the cytosines that remain (due to their protection by methylation). A PCR product
indicates the primer could anneal and reveals the methylation status. Like bisulfite
sequencing, this method is also not easily adapted to a genomic-scale based on the time
and expense associated with high throughput PCR.
The methylated DNA immunoprecipitation (MeDIP) method (36) uses an
antibody to capture DNA fragments by way of their methylated cytosines. The capture of
specific regions is expressed as a purification enrichment and can be determined using
PCR or by hybridizing the material to genomic chip arrays. The latter platform allows the
global determination of methylated regions. Because this method does not detect
unmethylated cytosines, a failure to detect a CpG region of interest could be due to its
hypomethylated state or a technique problem in the purification process.
Other methods of DNA methylation determination utilize the specificity of
restriction endonucleases for a particular CpG methylation state (methylation-sensitive
restriction enzyme; MSRE) followed by PCR analysis. An example of an MSRE is HhaI,
which recognizes and cuts 5’-GCGC-3’ sequences only when they are unmethylated (37).
PCR of the region will produce a visible product only when the included CpG is
methylated and thus protected from enzymatic digestion. This assay requires additional
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PCR controls to determine if failed PCR runs are due to poor primer design or if the
region is indeed hypomethylated.
This shortcoming can be resolved when two MSREs, with different methylation
sensitivities, are used. For example, HpaII and MspI are isoschizomers that both
recognize 5’-CCGG-3’ sequences. HpaII digestion is blocked when these sequences are
methylated, while MspI is insensitive to the methylation status of the recognition site.
When these fragments are cohybridized to genomic microarrays, (described as HpaII tiny
fragment Enrichment by Ligation-mediated PCR; or HELP assay) intergenomic and
intragenomic comparisons concerning DNA methylation can be made (38). Because this
method can detect methylated and unmethylated regions on a genomic scale, the HELP
assay is the method of choice for this study.
Materials and Methods
Overview
Figure 1 outlines the methods used to obtain the results. Briefly, cultured IMR-32
human neuroblastoma cells were differentiated and subsequently treated with beta
amyloid (Aβ). DNA from undifferentiated, differentiated, and Aβ-treated will be referred
to as undiff DNA, diff DNA, and Aβ DNA throughout the rest of this thesis, respectively.
DNA from each group was isolated, purified and then digested with either HpaII of MspI
restriction endonucleases. The DNA was then purified again and ligated to two sets of
adapters of known sequences. Ligation-mediated PCR was then used to amplify all
samples. A final purification procedure was performed before the samples were sent to
NimbleGen for fluorescent labeling and co-hybridization on promoter microarray. Raw
data from the microarrays were processed with computer software to
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Figure 1. Experimental Overview. DNA was isolated and purified from
differentiated, undifferentiated and A
Aβ-treated
treated cells and subsequently digested with
either HpaII or MspI restriction endonucleases. The DNA was then ligated to two sets
of adapters of known sequences. Ligation
Ligation-mediated
mediated PCR was then used to amplify all
samples. The samples were sent to NimbleGen for fluorescent labeling and coco
hybridization on a promoter microarray. Raw data from the micro
microarrays
arrays was processed
with computer software to determine and graph HpaII/MspI ratios for each probe.
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determine and graph HpaII/MspI ratios for each probe. Site-specific PCR was then
performed on several randomly chosen loci to validate the microarray data and establish
its biological significance. Regions of significant change in methylation were mapped to
nearby genes, which in turn were annotated to their corresponding cellular processes.
Cell Culture
Cholinergic IMR-32 human neuroblastoma cells (39) were grown and
differentiated according to the procedure outlined by Curran et al. (40). The cells were
depleted of fibroblasts through incubation with immunomagnetic anti-fibroblast
microbeads followed by separation with LD MACS columns, following the
recommendations of the manufacturer. The cells were maintained in culture in
proliferation medium (DMEM + glutamax, 5% FCS, 100 U/ml penicillin-streptomycin,
and 10 µg/ml gentamicin) at 37°C in an atmosphere of 5% CO2. The cells were plated at
a density of 5 × 105 cells/15 cm plate and grown for 48 hours in this proliferation media.
The proliferation media was then replaced by differentiation media (DMEM with
glutamax, 2% FCS, 2mM sodium butyrate, 100 U/ml penicillin-streptomycin, and 10
µg/ml gentamicin). The cells were maintained in differentiation media for 7 days, and
then treated with 25 µM Aβ1-40 peptide prepared as described in Chen et al.(30) or
vehicle for 48 hours. The cells were then rinsed with cold PBS (phosphate-buffered
saline), harvested by scraping, pelleted by centrifugation in 1.5 ml Eppendorf tubes, and
stored at -80°C.
DNA Isolation and Purification
The undifferentiated, differentiated, and Aβ-treated cell pellets were thawed and
kept on ice until they were treated with 478 µl of stop buffer (20% SDS, 5M NaCl,
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.5MEDTA), 20 µl protease K (2.5 mg/ml), and 2 µl RNase. The reagents were mixed
with the pellets by gentle agitation and the tubes were incubated in a 42°C water bath
overnight.
Each sample was treated with 500 µl of phenol-chloroform-isoamyl alcohol
(PCIAA) and incubated on a rotary wheel for 10 minutes at 37°C. The samples were then
separated into an organic and aqueous layer by centrifuging at 17,000×g for 5 minutes.
The aqueous layer containing the DNA in each sample was transformed to new 1.5 ml
Eppendorf tubes. This process was repeated once to ensure DNA purity.
To precipitate the DNA, 3× the sample volume in 100% ethanol was added along
with 1/10 the sample volume in 3M sodium acetate, and .5 µl of glycogen (20 mg/ml) to
each sample. The samples were then centrifuged at 17,000×g for 1 hour. The supernatant
was removed and the pellets were subsequently washed gently with 70% ethanol. The
pellets were finally resuspended in 200 µl of deionized water. The DNA in each sample
was then quantified using UV spectroscopy.
Digestion
Each sample was digested with HpaII and MspI in separate reactions. Each
reaction contained 1 µg of DNA and 4 µl of HpaII (10,000 U/ml) with 20 µl of New
England Biolabs Buffer 1, or 2 µl of MspI (20,000 U/ml) with 20 µl of NEB 4 and. The
reactions were brought to a final volume of 200 µl with deionized water and incubated
overnight in 37°C. The DNA from each sample was then purified as described above and
resuspended in 15.5 µl of 10 mM Tris-HCl (pH 8).
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Ligation
To avoid degradation or re-annealing of the sticky ends, the ligation was
performed immediately after the digestion. Two sets of adapters were used: NHpaII12
(5’-CGGCTTCCCTCG-3’), NHpaII24 (5’-GCAACTGTGCTATCCGAGGGAAGC-3’),
JHpaII12 (5’-CGGCTGTTCATG-3’), JHpaII24 (5’CGACGTCGACTATCCATGAACAGC-3’). The 24-mer and 12-mer oligonucleotides of
each set were annealed together in preparation for the ligation. Ligation was performed
on HpaII and MspI digested undiff DNA, diff DNA, and Aβ DNA. Reactions were
carried out in PCR tubes and consisted of 6 µl of 5× T4 ligase buffer (250 mM Tris-HCl
(pH 7.6), 50 mM MgCl2, 5 mM ATP, 5 mM DTT, 25% (w/v) polyethylene glycol-8000,
Invitrogen), 15.5 µl digested DNA, 4 µl of 50 µM pre-annealed JHpaII linkers, 4 µl of
µM pre-annealed NHpaII linkers, and 1 µl of T4 DNA ligase (4 U/ µl). The reactions
were put in a thermocycler at 16°C overnight. The reactions were then diluted to 10 ml
by 10 mM Tris-HCl (pH 8).
LM-PCR
The MspI digested DNA used in the amplification was half the volume of the
HpaII digested DNA. This is due to the difference in complexity of fragments in the MspI
digested DNA, which will cause these fragments to amplify and saturate the solution in
the PCR faster and undergo “extra” cycles without amplification. This makes the sample
susceptible to unwanted artifacts. This increased complexity in MspI fragments, and
circumventing this issue by use half as much MspI digested DNA as HpaII digested DNA
was previously reported(38). The LM-PCR reactions contained 5 µl of HpaII digested
DNA or 2.5 µl of MspI digested DNA, .5 µl of JHpa 24-mer oligonucleotide, .5 µl of
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NHpa 24-mer oligonucleotide, 25 µl of Supermix (Bio-Rad), and brought to a final
volume of 50 µl with deionized water. The LM-PCR scheme began with an initial
extension step at 72°C for 10 minutes, 15-20 cycles of annealing at 95°C for 30 seconds
and 72°C for 3 minutes, and a final extension step at 72°C for 10 minutes.
Purification
The reactions were purified using Qiagen’s QIAquick PCR Purification Kit (50)
according to the manufacturer’s instructions and DNA was quantified using UV
spectroscopy.
Microarray
Five 385K DNA Methylation microarrays were purchased from Roche
NimbleGen to hybridize 2 undiff DNA samples, 2 diff DNA, and 1 Aβ DNA. Following
quality control requirements by Roche NimbleGen for human DNA, all samples were
amplified to and purified to achieve a final mass of at least 4 µg of DNA and a
concentration of at least 250 ng/µl.
Data Analysis
The raw microarray data from Roche NimbleGen was processed using Matlab
2011. First, correlation graphs were generated to examine the relationship between the 2
undiff DNA microarrays and between the 2 diff DNA microarrays. Each array contained
4,288 random probes designed by Roche NimbleGen for control purposes. The
background fluorescence threshold was taken as 2.5 mean absolute deviations (MAD)
above the median fluorescence signal of the random probes (41, 42). For a probe to be
considered valid, both of its HpaII and MspI DNA signals have to be above the threshold,
and in all 3 conditions (undiff DNA, diff DNA, and Aβ DNA). An HpaII/MspI ratio
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histogram was generated for each condition (undifferentiated, differentiated, and Aβtreated). The undifferentiated and differentiated data were an average of 2 microarray
data sets for those conditions. The histograms were mean-centered and the x-axis was
converted from linear scale to log2.
Site-specific Confirmations
Site-specific qPCR confirmations were used to validate the microarray data and
show their biological significance. Undiff, diff, or Aβ DNA was digested with HpaII and
MspI in separate reactions as described above. An “uncut” control was included to serve
as a positive control for maximum amplification possible. The recipe for the uncut
digestion reaction was identical to that of MspI except that 2 µl of 50% glycerol were
added instead of the enzyme. The samples were subsequently purified as previously
described and resuspended in 200 µl of deionized water.
Initially, confirmations were aimed at exploring probes that exhibited
significantly more or less HpaII/MspI ratio than the mean. Another focus of those
confirmations was probes that showed the greatest changes in their HpaII/MspI ratio
between diff and Aβ DNA. Primers were designed around the closest 5’-CCGG-3’ to
such probes using Primer3 (http://frodo.wi.mit.edu/). The PCR product size range was
chosen to be between 80-140 bp, the primer Tm was 60±2, and the primer size was 20±2
bp. All other criteria were left as the default settings by the software. The 25 µl qPCR
reactions contained .015-.025 µg of HpaII or MspI-digested DNA or uncut DNA, 12.5 µl
Supermix, and forward and reverse primers with a final concentration of .625 µM each.
Reactions lacking DNA template were also included as control for primer self-annealing
and amplification. Amplification was performed using a BioRad MJ Mini Personal
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Thermal Cycler. The touchdown qPCR scheme began with an initial melting step at 95°C
for 5 minutes. The first cycle was repeated 19 times and consisted of a melting step at
94°C for 10 seconds, followed by annealing at 69°C for 30 seconds, and a final extension
step at 72°C for 30 seconds. The annealing step decreased by .5°C each cycle. The
second cycle followed immediately and consisted of a melting step at 94°C for 10
seconds, annealing at 59°C for 30 seconds, and then an extension step at 72°C for 30
seconds. This second cycle was repeated 24 times with a constant annealing temperature,
and was followed by a final extension step at 72°C for 5 minutes. The amplification
graphs were generated by BioRad CFX Manager 2.0. The quantification cycle (Cq)
values were obtained by positioning the artificial horizontal line within the linear phase
of amplification for all three curves - uncut, MspI, and HpaII DNA – for each primer pair
(Figure 2).

Cq
HPAII
THRESHOLD

UNCUT

MSPI

Figure 2. Determining Cq values. The graph represents a typical graph generated at
the end of a qPCR run. Each curve represents relative fluorescence readings from one
well after each cycle. The artificial threshold line is positioned so that it is across the
linear phase of all curves in question for a given primer pair. The point at which the
threshold line intersects with a curve represents the Cq value for that curve.
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Gene Ontology
Gene symbols were linked to the 222 most changing regions, 111 regions
becoming hypomethylated and 111 regions becoming hypermethylated, by plugging the
region names into GREAT, a region/gene association and annotation software developed
by Stanford University and Bejarano Lab (43). Human genome 18 was used for the
species assembly and the whole genome for the background regions. This software
developed graphs representing the number of associated genes per region, distance to
TSS, and absolute distance to TSS. Under the global controls options, “View all regiongene associations” was chosen to obtain all of the gene symbols for the inputted regions.
These gene symbols were then plugged into GeneCodis (44-46), a gene annotation
website; homosapiens was used as the organism and biological processes was selected for
genome wide assessment. The gene symbols of the regions becoming more
hypomethylated, more hypermethylated, a combined list, and a random list of 111
regions from the microchip data were assessed using the following G.O. requirements:
level 7 (the most stringent), a minimum of 3 genes associated with that ontology, a chi
square value that was lower than the lowest obtained chi square value from the random
list. False discovery rate was used to find a corrected chi square value. The enrichment
value from which the chi-square value was obtained was calculated by dividing the ratio
of genes for a gene ontology in the list to the total number of genes in the list by the ratio
of genes for that gene ontology in the genome to the total number of genes in genome.

Number of Genes for G.O. in List
ቁ
ቀ
Number of Genes in List
Total Number of Genes for G.O.
ቀTotal Number of Genes in Genomeቁ
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The gene ontologies that met these requirements and were associated with the
central nervous system were charted and linked with their gene symbols.
Results
Global DNA Methylation Distribution in Neurons Remains Largely Unchanged
after Aβ Treatment in Vitro
IMR-32 human neuroblastoma cells were differentiated and subsequently treated
with Aβ or vehicle for 48 hours. DNA from experimental and control cells was isolated,
differentially digested with HpaII and MspI, amplified, and hybridized to a promoter
microarray. Analysis of the microarray data revealed a bimodal frequency distribution of
the fluorescent loci in the control sample, a distribution that remains largely unchanged in
the Aβ treated sample (r=.9870) (Figure 3A and B). The bimodal distribution of the data
is consistent with the expectation that CpG dinucleotides fall into hypomethylated or
hypermethylated categories. The overall consistency of the distribution after Aβ
treatment suggests that only a select few genetic loci – corresponding to certain cellular
processes – are epigenetically affected by Aβ.
Site-specific qPCR Confirms the Microarray Data
Since DNA methylation decreases from left to right along the x-axis in Figure 3A
and B, it is expected from a probe which has an HpaII/MspI ratio higher than the average
of the red curve to have a nearby CCGG that is less methylated in comparison to a CCGG
laying close to a probe with a ratio lower than the mean of the blue curve. To confirm the
predictions of the microarray, regions (A “region” is a chromosomal range that
encompasses a group of neighboring probes. These chromosomal ranges were specified
by NimbleGen in the raw data output and serve as “parent” designations for the included
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More Methylation

Less Methylation

More Methylation

Less Methylation

Figure 3. Global DNA Methylation Distribution in Neurons Remains Largely
Unchanged After Aβ Treatment in Vitro. (A and B) The log2 HpaII/MspI ratios for
the control and Aβ-treated microarray probes are plotted as frequency distributions.
The data are mean-centered at zero (vertical grey line), with negative ratios and
positive ratios signifying loci more and less methylated than the mean level of
methylation, respectively. The blue and red curves represent the two components of
the bimodal distribution. Each curve shows the probability of the data of each bin
belonging to the left peak or the right peak of these bimodal distributions. (A) The
mean HpaII/MspI ratios of the blue and the red curve are -0.66 and 1.76, respectively.
(B) The mean HpaII/MspI ratios of the blue and the red curve are -0.76 and 1.95,
respectively.
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probes) were randomly chosen from a list of candidates that have 2-5 probes with an
HpaII/MspI ratio higher than the mean of the red curve or lower than the mean of the
blue curve. In those regions, we used qPCR to target a CCGG that was (1) lose to the
probe(s) which qualified the region for this analysis and (2) had an appropriate
surrounding DNA complexity to facilitate specific primer design.
Figure 4A showcases a region that has two probes with ratios higher than the
average of the red curve in the control sample frequency distribution (Figure 3A). For
comparison, Figure 4B shows a region that has 4 probes with ratios lower than the
average of the blue curve in the same frequency distribution. Accompanying qPCR
graphs of the highlighted CCGGs show approximately 40 times difference in
methylation. In other words, in the population of differentiated IMR-32 cells, the CCGG
in Figure 4A is 40 times less methylated than the CCGG in Figure 4B.
We performed the same confirmation experiments on data from the Aβ
microarray (Figure 5A and B). The chromosomal region in Figure 5A has 5 probes with
HpaII/MspI ratios higher than the average of the red curve in Figure 3B. The region in
Figure 5B has 3 probes with ratios lower than the average of the blue curve in Figure 3B.
Looking at the two accompanying qPCR graphs, it is apparent that the CCGG in Figure
5B is approximately 15 times more methylated than the CCGG in Figure 5A in the
population of Aβ-treated neurons. These results demonstrate that the probe ratios are
indicative of actual methylation levels of nearby CpGs. Therefore, biologically
significant conclusions can be reliably obtained from the microarray data.
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Figure 4. Site-specific qPCR Confirms the Microarray Data (Control Sample). (A
and B) The landscapes of microarray regions selected for confirmations are plotted
with purple bars representing the probes and blue circles showing the CCGG loci in
those regions. The qPCR results for the chosen CCGGs (red circles) are generated by
setting the 2^(-(Cq)) of the MspI-digested DNA qPCR curve to “1” and setting the
HpaII bar to represent the value of 2^(-(CqHpaII-CqMspI)).
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Figure 5. Site-specific qPCR Confirms the Microarray Data (Aβ Sample). (A and
B) The landscapes of microarray regions selected for confirmations are plotted with
purple bars representing the probes and blue circles showing the CCGG loci in those
regions. The qPCR results for the chosen CCGGs (red circles) are generated by setting
the 2^(-(Cq)) of the MspI-digested DNA qPCR curve to “1” and setting the HpaII bar
to represent the value of 2^(-(CqHpaII-CqMspI)).
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Aβ Induces High Changes in Methylation Levels in a Subset of Loci
Although Figure 3 showed that the global DNA methylation status of the control
sample genome does not change after treating the cells with Aβ, specific loci may still
undergo change in methylation levels in response to Aβ treatment. Subtracting the
HpaII/MspI ratios of the control microarray from the Aβ microarray produces the normal
distribution shown in Figure 6A. Probes from only 0.05% of either end of the normal
distribution were used for further confirmations and gene ontology analysis (Figure 6B
and C). This portion represents a group of probes that changed their signal the most in
response to Aβ treatment. With such stringency, we are eventually ensuring the selection
of the biological processes that are most affected by Aβ treatment.
Aβ-induced Probe Ratio Changes Correspond to CpG Methylation Changes
Figures 4 and 5 demonstrate that the control sample and Aβ sample microarrays
are successful in predicting CpG methylation differences within each sample. However,
before proceeding with gene ontology analysis, it was necessary to confirm that a ratio
change of the same given probe between the control sample and the Aβ sample
microarrays corresponds to a same-CpG change in methylation between the control DNA
and Aβ-treated DNA. Probes were chosen randomly from the “upper” and “lower” 0.05%
of the most changing probes and qPCR was performed on the upstream and downstream
CCGGs flanking each chosen probe in differentiated DNA and Aβ-treated DNA. Figure
7A contains a landscape of a region with a probe that shows a significant increase in
HpaII/MspI ratio, and Figure 7B shows a region with a probe that displays a significant
decrease between the control sample and the Aβ-treated sample. The
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Figure 6. Aβ Induces High Changes in Methylation Levels in a Subset of Loci. (A)
The data from the control microarray are subtracted from the Aβ data, and the result is
plotted as a frequency distribution. The two vertical lines represent the “upper” and
“lower” 0.05% cutoff positions in respect to the rest of the distribution. (B) A close-up
frequency distribution of the “lower” 0.05% of the probes with the highest decrease in
HpaII/MspI ratio (C) A close-up frequency distribution of the “upper” 0.05% of the
probes with the highest increase in HpaII/MspI ratio.
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Figure 7. Aβ-induced Probe Ratio Changes Correspond to Methylation Changes
at Nearby CpGs. (A and B) The landscapes of microarray regions selected for
confirmations are plotted with purple bars representing the (Aβ-control) value for the
probes and blue circles showing the CCGG loci in those regions. The “control” and
“AB” bars in the qPCR graphs represent the value of 2^(-(CqHpaII-CqMspI)) in the
control and Aβ sample DNA, respectively.
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accompanying qPCR graphs for each region demonstrate that the change in probe ratios
are confirmed with parallel changes in CpG methylation levels after Aβ treatment.
Aβ alters the DNA Methylation of Cell Fate Genes
The low number of high changes in probe ratios as seen in Figure 6 suggests that
Aβ alters only a handful of cellular processes epigenetically in vitro. To shed light on
these cellular processes, we mapped the 222 chromosomal regions that contained the
highly changing probes to nearby genes using GREAT online software. Some regions
were as close as 70-300 bp away from the nearest genes, while other regions were more
than 150,000 bp away (data not shown). The output gene symbols were then annotated
using GeneCodis online software. GeneCodis also generated p-values indicating the
likelihood of several genes belonging to the same gene ontology being inour list of
annotated genes. The results showed high levels of enrichment for genes associated with
neuron differentiation, neurogenesis, and apoptosis (Table 1). Although Aβ treatment
does not change the global DNA methylation status of the genome, it seems to effectively
target select loci that have high impact on the fate of the cells. The probability that a
number of genes in one ontology would appear in our list together can be contrasted with
the probability of a random number of genes and their ontologies appearing in a list the
same size as ours (Table 1).
To shed light on the probe ratio changes in respect to the landscape of one of our
significant genes, we plotted the TSS of DLX1 and the regions associated with it,
including the most significant changing probe that mapped to DLX1 in GREAT (Figure
8). The five regions surrounding the TSS showed small ratio changes in both directions.
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Table 1. Aβ alters the DNA Methylation of Cell Fate Genes
Genes. Parent region names
of the “upper” and “lower” 0.05% most changing probes after A
Aβ
β treatment were
mapped to the closest known genes. The generated list of gene names was annotated
using GeneCodis. The pp-valuess in this table represent the likelihood of a number of
genes belonging to the same ontology to be in the same list of genes. A list of random
genes of the same size as our list was also entered in GeneCodis to generate p-values
p
associated with the likelih
likelihood
ood of random genes with random ontologies being in a list
the same size as ours. For stringency purposes, all ontologies listed have a p-value
p
smaller than the p-value
value of the random list except for the first two pp-values
values which are
high due to the fact thatt all the genes that belong to those ontologies in the genome are
in our list. Enrichment was calculated using the compound fraction described in the
Materials and Methods section.
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Figure 8. High Loss of Methylation Downstream of DLX1 TSS. The figure shows a
landscape of the five regions around the TSS of DLX1. The y-axis represents (Aβcontrol) probe ratios and the x-axis represents the chromosomal position. The
rightmost region was the region that led to DLX1 in GREAT.

The most significant probe lies in a region that is approximately 6000 bp
downstream of the TSS, indicating a high loss of methylation at that region.
Discussion
Our data reveal that the global DNA methylation status of the genome does not
change when differentiated IMR-32 cells are treated with Aβ in vitro. However, lack of a
global change in DNA methylation does not rule out changes at specific loci. Indeed, we
confirmed that Aβ induces change in DNA methylation at discrete loci which are
associated with cell fate genes such as neuron differentiation and apoptosis.
When we observed a change in the HpaII/MspI ratio of a given probe, it was not
possible to pinpoint with absolute certainty which CCGG around that probe was changing
its methylation level and producing the change in the ratio. For that reason, we chose our
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method of testing one downstream and one upstream CCGG of the probe of interest. It
should be noted that it could be changes in methylation in farther CCGG that produce the
changes in probe ratios. However our high rate of confirmation on the upstream and
downstream CCGGs reveals the high likelihood that changes in DNA methylation by Aβ
are not pinpoint processes, but when there is a methylation change at one CpG it is likely
that neighboring CpGs follow.
After mapping the microarray regions that showed significant change in
methylation to nearby genes, we found that some regions were 70-300 bp away from the
nearest genes, while other regions were more than 150,000 bp away. Although some high
changes in methylation are fairly distant from the TSS, it is well-established that gene
regulation can proceed distally through enhancer mechanisms (for review see (47, 48)).
Future studies can focus on those regions and evaluate their candidacy as possible distal
enhancer regions. It is also important to note that GREAT software maps regions to the
closest “canonical” TSS of a given gene. It is possible, then, that GREAT is ignoring
potentially closer TSS sites. In other words, some of the regions that highly change their
methylation status in our data may be closer to a nearby gene than the data may seem to
suggest.
A previous study by Cobos et. al. shed light on the involvement of DLX
transcription factors on the migration and differentiation of GABAergic interneurons
(49). Interestingly, they found that DLX1/2 double mutant mice have interneurons that
fail to migrate from the subpallium to the cortex and show immature increase in neurite
growth. These results demonstrated the importance of DLX1 and DLX2 in the repression
of neurite growth and maintaining a compact cell shape that is necessary for easy
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migration maneuvers. With these previous findings in mind, our data seems to suggest
the involvement of Aβ in “de-differentiating” neurons and the consequent loss of their
specific functions. Such effect could lead to the memory loss and aberrant brain function
accompanied by AD. We therefore encourage future research to directly examine the
expression levels of DLX1 in AD brain tissue as that may be a key step in pathogenesis.
Conclusion
We can make three conclusions from the results presented herein. First, Aβ
treatment of differentiated neurons in vitro does not change the global DNA methylation
levels of the genome. There is an overall consistency in the structure of the distribution of
methylation levels before and after Aβ treatment. There is also a high correlation in ratio
values between the control sample probes and the Aβ sample probes of the same loci.
Second, exposure to Aβ does lead to significant changes in methylation at a subset of
loci. Although the majority of the loci show largely unchanged methylation levels, some
loci show high changes in DNA methylation following Aβ treatment. Third, these loci are
associated with genes involved in neuronal differentiation, neurogenesis, and apoptosis
control. Therefore, Aβ seems to contribute to AD progression through propagating
neuronal loss of function and death.
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